Publicacións (19) Publicacións de Julio Vázquez Rodríguez

filter_list Internal Medicine

2016

  1. A single-institution analysis of the effect on local control of high-dose rate brachytherapy boost in a single 7 Gy fraction

    Revista de Senologia y Patologia Mamaria, Vol. 29, Núm. 2, pp. 63-68

  2. Expression and Clinical Significance of Metalloproteases and Their Inhibitors by Endothelial Cells From Invasive Breast Carcinomas

    Clinical Breast Cancer, Vol. 16, Núm. 4, pp. e83-e91

2015

  1. A phenotype from tumor stroma based on the expression of metalloproteases and their inhibitors, associated with prognosis in breast cancer

    OncoImmunology, Vol. 4, Núm. 7, pp. 1-11

2009

  1. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas

    Breast Cancer Research and Treatment, Vol. 116, Núm. 1, pp. 39-52

2008

  1. Androgen receptor expresion in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors

    BMC Cancer, Vol. 8

2007

  1. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse

    British Journal of Cancer, Vol. 97, Núm. 7, pp. 957-963

  2. Study of matrix metalloproteinases and their inhibitors in breast cancer

    British Journal of Cancer, Vol. 96, Núm. 6, pp. 903-911

2006

  1. Cytosolic levels of TFF1/pS2 in breast cancer: Their relationship with clinical-pathological parameters and their prognostic significance

    Breast Cancer Research and Treatment, Vol. 96, Núm. 1, pp. 63-72

2005

  1. Clinical significance of cathepsin D concentration in tumor cytosol of primary breast cancer

    International Journal of Biological Markers, Vol. 20, Núm. 2, pp. 103-111

  2. Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA)

    Journal of Cancer Research and Clinical Oncology, Vol. 131, Núm. 11, pp. 701-714

  3. Expression and prognostic value of EGFR in invasive breast cancer

    Oncology Reports, Vol. 14, Núm. 6, pp. 1655-1663

  4. Tissue-Type plasminogen activator (tPA) in breast cancer: Relationship with clinicopathological parameters and prognostic significance

    Breast Cancer Research and Treatment, Vol. 90, Núm. 1, pp. 33-40

2003

  1. Significación clínica del contenido tumoral del receptor del factor de crecimiento epidérmico en el cáncer de mama

    Revista Espanola de Medicina Nuclear, Vol. 22, Núm. 6, pp. 386-394

2002

  1. Analysis of the cytosolic content of the pS2 protein in breast cancer

    Revista Espanola de Medicina Nuclear, Vol. 21, Núm. 1, pp. 28-33

  2. Expression and clinical significance of pepsinogen C in epithelial ovarian carcinomas

    European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 104, Núm. 1, pp. 58-63

  3. Importancia de la edad como factor pronóstico determinante de la variabilidad de las características clínico-patológicas de las pacientes con cáncer de mama

    MEDIFAM - Revista de Medicina Familiar y Comunitaria, Vol. 12, Núm. 6, pp. 379-386

2001

  1. Lysozyme expression by breast carcinomas, correlation with clinicopathologic parameters, and prognostic significance

    Annals of Surgical Oncology, Vol. 8, Núm. 8, pp. 667-674

2000

  1. Apolipoprotein D expression in metastasic lymph nodes of breast cancer.

    International journal of surgical investigation, Vol. 2, Núm. 4, pp. 285-293

1997

  1. Clinical significance of preoperative serum levels of CA 125 and TAG-72 in ovarian carcinoma

    International Journal of Biological Markers, Vol. 12, Núm. 3, pp. 112-117